The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease

Larsen, Lone; Jensen, Michael Dam; Larsen, Michael Due; Gaardskjær Nielsen, Rasmus; Thorsgaard, Niels; Vind, Ida; Wildt, Signe; Kjeldsen, Jens

Published in:
Clinical Epidemiology

DOI:
10.2147/CLEP.S99478

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 23. dec., 2018
The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease

Lone Larsen¹
Michael Dam Jensen²
Michael Due Larsen³
Rasmus Gaardskær Nielsen⁴
Niels Thorsgaard⁵
Ida Vind⁶
Signe Wildt⁷
Jens Kjeldsen⁸

¹Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg,
²Department of Internal Medicine, Section of Gastroenterology, Lillebaelt Hospital Vejle, Vejle,
³Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark,
⁴Department of Paediatrics, Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense C,
⁵Department of Internal Medicine, Section of Gastroenterology, Hospital Unit West, Herning,
⁶Department of Gastroenterology, Copenhagen University Hospital, Hvidovre,
⁷Department of Medicine, Section of Gastroenterology, Koge Hospital, Koge,
⁸Department of Medical Gastroenterology, Odense University Hospital, Odense C, Denmark

Correspondence: Lone Larsen
Department of Gastroenterology and Hepatology, Aalborg University Hospital, Mølleparkvej 4, DK-9000 Aalborg, Denmark
Tel +45 9766 3500
Fax +45 9766 3577
Email lone.larsen@rn.dk

Aim: The aims of The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease are to ensure that biological therapy and the clinical management of patients with inflammatory bowel disease (IBD) receiving biological treatment are in accordance with the national clinical guidelines and, second, the database allows register-based clinical epidemiological research.

Study population: The study population comprises all Danish patients with IBD (both children and adults) with ulcerative colitis, Crohn's disease, and IBD unclassified who receive biological therapy. Patients will be enrolled consecutively when biological treatment is initiated.

Main variables: The variables in the database are: diagnosis, time of diagnosis, disease manifestation, indication for biological therapy, previous biological and nonbiological therapy, date of visit, clinical indices, physician's global assessment, pregnancy and breastfeeding (women), height (children), weight, dosage (current biological agent), adverse events, surgery, endoscopic procedures, and radiology.

Descriptive data: Eleven clinical indicators have been selected to monitor the quality of biological treatment. For each indicator, a standard has been defined based on the available evidence. National results will be published in an annual report and local results on a quarterly basis. The indicators will be reported as department-specific proportions with 95% confidence intervals, and the national average will be provided for comparison. An estimated 1,200–1,300 new biological therapiestes initiated each year in Danish patients with IBD.

Conclusion: The database will be available for research during 2016. Data will be made available by The Danish Clinical Registries (www.rkkp.dk).

Keywords: inflammatory bowel disease, biological therapy, anti-TNF-α agents, quality indicators, database

Background

The incidence of inflammatory bowel disease (IBD) is increasing worldwide including Denmark.¹–⁴ During the last decades, introduction of biological therapy has changed the management of ulcerative colitis (UC) and Crohn’s disease (CD).³ As a consequence, the medication-related expenses of IBD therapy have increased substantially.⁵ International and national treatment guidelines support clinicians in treatment decisions and rational clinical use of biological therapy and are used by health care providers to prioritize and regulate the costs of therapy.

Aim of The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease

To ensure a rational use of biological drugs and adherence to national guidelines, The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease...
(BIO-IBD) has been established in 2015. First, the aim of the database is to ensure that the choice of biological therapy and the clinical management of patients with IBD receiving biological treatment are in accordance with the national clinical guidelines and second, the database can be used for register-based clinical epidemiological research.

The database is planned to start in March 2016, and patients will be enrolled consecutively when biological treatment is initiated. Based on recent data from The Danish National Patient Registry (NPR), we estimate that 1,200–1,300 new biological therapies are initiated each year and at a given point in time 2,700–2,800 patients are treated with biological agents.

**Study population**

In Denmark (population of ~5.5 million people), all citizens have free access to a tax-supported health care system, and biological therapy is only administered in public hospitals without cost to the patient.

For all Danish hospitals, both public and private, it is mandatory by Danish law to report diagnosis and clinical procedures to NPR. The completeness of coding in NPR is very high as 99% of all hospital discharges and out-patient procedures to NPR. The completeness of coding in NPR is very high as 99% of all hospital discharges and out-patient clinics from somatic hospitals are recorded. Likewise the completeness of diagnoses of IBD in NPR is very good. In one study, the validity of the IBD diagnoses in NPR was examined using the pathology system as a reference standard, confirming that 94% of the UC and CD diagnoses were included in the NPR. The overall validity of diagnoses of CD in the NPR was 97%, and for UC 90%. Identification of patients is based on the Danish Civil Registration System (CRS). The CRS has registered all persons alive and living in Denmark since 1968, and has a very high accuracy of Danish citizens and migrations.

The availability of these nationwide Danish registries makes it possible to retrieve data on almost all patients with IBD and treatment with biological agents. Hence, the study population comprises all Danish patients with IBD (both children and adults) with UC, CD, and IBD-unclassified (IBD-U) who receive biological therapy. Patients will be enrolled consecutively when biological treatment is initiated. Eligible patients with IBD are bio-naive patients (patients never treated with biological therapy), patients previously treated with biological therapy and stopped for >3 months, and patients already on biological therapy who, due to side effects or lack of effect, switch to another biological drug.

It is mandatory for the departments prescribing biological therapy to report these data to the BIO-IBD registry.

**Quality indicators**

Eleven quality indicators have been defined (Table 1). Choice, background, and level of evidence for the indicators

**Table 1 Quality indicators**

<table>
<thead>
<tr>
<th>Quality indicator</th>
<th>Indicator standard (%)</th>
<th>Type of indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>1CD: Percentage of patients with luminal CD for whom the indication for biological therapy is in accordance with the national guidelines</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>2CD: Percentage of CD patients with no prior biological therapy for whom the selected first-line biological therapy is in accordance with the national guidelines</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>3CD: Percentage of patients with CD in maintenance therapy with a biological agent, who have a minimum of two outpatient visits per year</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>4CD: Percentage of patients in maintenance therapy with a biological agent, diagnosed with luminal CD, never having undergone surgery for CD, who have well-controlled disease (HBI score &lt;5 or abrPCDAI &lt;10)</td>
<td>≥60</td>
<td>Outcome</td>
</tr>
<tr>
<td>5UC: Percentage of patients with UC for whom the indication for biological therapy is in accordance with the national guidelines</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>6UC: Percentage of UC patients with no prior biological therapy and chronic active disease for whom the selected first-line biological therapy is in accordance with the national guidelines</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>7IBD: Percentage of UC patients with acute severe ulcerative colitis for whom the selected first-line biological therapy is in accordance with the national guidelines</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>8UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have a minimum of two outpatient visits per year</td>
<td>≥80</td>
<td>Process</td>
</tr>
<tr>
<td>9UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have well-controlled disease (SCCAI &lt;5 or PUCAI &lt;10)</td>
<td>≥60</td>
<td>Outcome</td>
</tr>
<tr>
<td>10IBD: Percentage of patients with UC or CD, who are in steroid free remission after at least 6 months of biological therapy</td>
<td>≥40</td>
<td>Outcome</td>
</tr>
<tr>
<td>11IBD: Percentage of children with UC or CD in maintenance therapy with a biological agent, for whom data on height and weight is recorded in minimum two outpatient visits per year</td>
<td>≥60</td>
<td>Process</td>
</tr>
</tbody>
</table>

**Abbreviations:** abrPCDAI, Abbreviated Pediatric Crohn’s Disease Activity Index; CD, Crohn’s disease; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; PUCAI, Pediatric Ulcerative Colitis Index; SCCAI, Simple Clinical Colitis Activity Index; UC, ulcerative colitis.

Larsen et al. Clinical Epidemiology 2016:8
Indicators related to outcome represent clinically relevant measures, with indicator standards determined from existing literature. Indicators related to process are addressing guideline adherence and administrative issues, with indicator standards determined from consensus in the working group.

In the future, new quality indicators are to be defined and added to the registry.

Main variables

The variables in the database are obtained by two methods: Data from NPR are used for registration of the IBD patient and basic information on diagnosis, use of biologic agent, and IBD-related procedures. This is supplemented with clinical information reported by the clinician using a national web-based input module (Supplementary materials 1, 2, and 3). This is believed to ensure the best possible data quality.

1. Data harvested from NPR: diagnosis, previous biological therapy, surgery, endoscopic procedures, radiology, treatment dates regarding current biological therapy, and current biological agent (Table 2).

2. Data reported by the clinician include: background information (diagnosis, time of diagnosis, disease manifestation, indication for biological therapy, and previous nonbiological therapy) and contact data at outpatient visit (date of the visit, relevant clinical indices [see later], physician’s global assessment, pregnancy/breastfeeding [women], height [children], weight, dosage [current biological agent], nonbiological therapy, adverse events with regard to the biological agent, and treatment decision on continuing, changing, or stopping the biological agent).

3. The clinical indices used in the database are:
   - Harvey-Bradshaw Index for CD
   - Abbreviated Pediatric Crohn’s Disease Activity Index for children with CD
   - Simple Clinical Colitis Activity Index for UC and IBD-U

![Figure 1 Patient flow in the database.](https://www.dovepress.com/)

**Notes:** Patients will be included at start or switch of biological therapy. A form for basic patient information, start of biological therapy, outpatient visit where biological therapy will be administered, switch of therapy, and discontinuation of biological therapy will be available at relevant time-point in course of therapy.
Pediatric Ulcerative Colitis Activity Index for children with UC and IBD-U\textsuperscript{17}

- Short Health Scale.\textsuperscript{16,19}

A complete list of the variables can be found in Supplementary material 2.

**Data recording**

The clinician is required to ensure that every eligible patient is entered into the database upon start of biological therapy. It is recommended that data are entered in the database every time biological treatment is administered, but as a minimum twice yearly and every time changes in therapy, or side-effects occur or if therapy is stopped. In addition to this, there is a continuous data collection from the NPR, which will ensure that all eligible patients are registered, should the clinician fail to include the patient at the first visit. To ensure the completeness of the database, the departments involved in administering biological treatment will receive lists of patients with records of biological treatment codes from the NPR.

The quality of data in the database relies entirely on the clinician/IBD nurse and is the responsibility of the department giving biological treatment. It will only be possible to calculate the quality indicators if sufficient data is reported in the database. If it is not possible to calculate the indicators, the departments with incomplete data will be mentioned in the annual report. There is no official quality control but as the results are a public document and reported on a quarterly basis to the departments to regularly review their clinical performance, it is believed to motivate the clinicians to high quality in both treatment and reporting.

**Examples of research**

The database will be available for research during 2016. Data will be made available by The Danish Clinical Registries (RKKP; [www.rkkp.dk](http://www.rkkp.dk)).

**Administrative issues and funding**

The database is administered by a steering committee, which comprises:

- Five members of the Danish Society of Gastroenterology and Hepatology (one member from each of the five regions in Denmark)
- A pediatric gastroenterologist, member of the Danish Pediatric Society
- A documentarist (clinician to compose a report on the background and evidence for the indicators)

### Table 2 Codes from The Danish National Patient Registry to be included in the Danish Registry for Biological Therapy: ICD-10 diagnostic codes used to identify patients with IBD

<table>
<thead>
<tr>
<th>Condition</th>
<th>Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crohn's disease</td>
<td>K50.0–50.9</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>K51.0–51.9</td>
</tr>
<tr>
<td>IBD unclassified</td>
<td>K51.9, K52.9</td>
</tr>
</tbody>
</table>

**Operation codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOHJ18A1</td>
<td>Infliximab</td>
</tr>
<tr>
<td>BOHJ18A3</td>
<td>Adalimumab</td>
</tr>
<tr>
<td>BOHJ18A4</td>
<td>Golimumab</td>
</tr>
<tr>
<td>BOHJ18A5</td>
<td>Certolizumab pegol</td>
</tr>
<tr>
<td>BOHJ26</td>
<td>Natalizumab</td>
</tr>
<tr>
<td>BOHJ19H4</td>
<td>Vedolizumab</td>
</tr>
</tbody>
</table>

**MRI**

- UXMD: MRI of abdomen and pelvis
- UXMD10: MRI of upper abdomen
- UXMD15: MRI of lower abdomen, including pelvis
- UXMD20: MRI of retroperitoneum

(Continued)
A RKKP-team (Danish Clinical Quality Databases represented by the Centre of Competence for Nationwide Clinical Registries) assigning a contact person, a data manager, an epidemiologist, and a statistician.

The members are appointed for a period of 4 years by the board of the respective societies. There is an option for one re-election.

The steering committee has no financial means of its own, but the Danish Regions’ funding for clinical quality registries has secured a grant for the establishment of the database.

The BIO-IBD database operates under the Danish law on data protection, with license granted by the Danish Data Protection Agency and the Danish National Board of Health. Further individual patient consent or Ethical Review Board approval is not required according to Danish law when data are used to monitor, secure, and improve clinical quality.

**Conclusion**

Based on the indicators defined, an annual report will state the quality of biological therapy in patients with IBD treated in Denmark, both at a national and department level together with a complete overview of the data available.

In addition, results are reported on a quarterly basis to the departments to regularly review their clinical performance. The indicators will be reported as department-specific proportions with 95% confidence intervals, and the national average will be provided for comparison. For each indicator, a standard has been developed based on the available evidence.

**Acknowledgments**

The authors would like to thank all members of the steering committee for their contribution in the development the BIO-IBD database. The members of the steering committee are Data Manager, Pia Andersen, MSc, Katrine Abildstrup Nielsen, MSc in Health Science, Esra Öztoprak, MSc in Health Science, all from The Danish Clinical Registries—a National quality improvement program, Statistician Jan Nielsen, MSc, PhD, and Bente Nørgaard, MD, PhD, DMSc. This paper was funded by the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation and administered by the Danish Regions.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**